New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
12:43 EDTMNTAMomenta Pharma petition for rehearing denied by Court of Appeals
Momenta Pharmaceuticals announced that the United States Court of Appeals for the Federal Circuit denied its request for a rehearing en banc to reconsider its three-judge panel opinion in the case of Momenta Pharmaceuticals vs. Amphastar Pharmaceuticals, Inc. The request for all active judges of the court to reconsider a panel decision, known as rehearing en banc, is only granted upon a majority vote. "We will continue to pursue our appellate options and we plan to file a petition for certiorari, asking the Supreme Court to review this case," said Craig Wheeler, president and CEO of Momenta.
News For MNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTMNTAOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
08:48 EDTMNTAMomenta downgraded to Sell with $7 price target at Maxim
Maxim downgraded Momenta Pharmaceuticals two notches to Sell from Buy and cut its price target for shares to $7 from $17. The firm lowered its revenue assumptions for Copaxone after the Supreme Court sent the patent suit back to the Court of Appeals Federal Circuit.
07:23 EDTMNTAMomenta downgraded to Sell from Buy at Maxim
January 22, 2015
11:52 EDTMNTAMomenta sell-off provides good entry point, says Brean Capital
Subscribe for More Information
January 21, 2015
08:38 EDTMNTAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
January 20, 2015
10:40 EDTMNTAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use